TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference
Rhea-AI Summary
TELA Bio (NASDAQ: TELA) will present at the Piper Sandler 37th Annual Healthcare Conference. Management is scheduled to present on December 3, 2025 at 2:30 pm ET. Interested parties can access a live and archived webcast at the company's investor site: ir.telabio.com.
The presentation highlights the company’s participation at a major healthcare investor conference and provides a webcast option for remote access.
Positive
- None.
Negative
- None.
News Market Reaction 5 Alerts
On the day this news was published, TELA declined 8.47%, reflecting a notable negative market reaction. Argus tracked a peak move of +2.6% during that session. Argus tracked a trough of -9.1% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $46M at that time.
Data tracked by StockTitan Argus on the day of publication.
MALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler’s 37th Annual Healthcare Conference.
TELA’s management is scheduled to present at Piper Sandler’s 37th Annual Healthcare Conference at 2:30 pm ET on December 3rd, 2025. Interested parties can access the live and archived webcast at ir.telabio.com.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Investor Contact
Louisa Smith
ir@telabio.com